Arcus Biosciences, Inc. logo

Arcus Biosciences, Inc.

NYSE:RCUS

Overview | Financials
Company Name Arcus Biosciences, Inc.
Symbol RCUS
Currency USD
Price 15.81
Market Cap 1,437,966,930
Dividend Yield 0%
52-week-range 12.95 - 25.47
Industry Biotechnology
Sector Healthcare
CEO Dr. Terry J. Rosen Ph.D.
Website https://www.arcusbio.com

An error occurred while fetching data.

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The

Related Stocks

Avanos Medical, Inc. logo

Avanos Medical, Inc.

AVNS

20.18 USD

Taro Pharmaceutical Industries Ltd. logo

Taro Pharmaceutical Industries Ltd.

TARO

42.73 USD

Paragon 28, Inc. logo

Paragon 28, Inc.

FNA

6.58 USD

U.S. Physical Therapy, Inc. logo

U.S. Physical Therapy, Inc.

USPH

95.08 USD

Cano Health, Inc. logo

Cano Health, Inc.

CANO

2.3 USD

Bright Health Group, Inc. logo

Bright Health Group, Inc.

BHG

16.35 USD

Nevro Corp. logo

Nevro Corp.

NVRO

9.45 USD

Brookdale Senior Living Inc. logo

Brookdale Senior Living Inc.

BKD

6.73 USD

Oscar Health, Inc. logo

Oscar Health, Inc.

OSCR

19.06 USD

Financials

Numbers are in millions USD

Numbers are in millions USD